Status:
UNKNOWN
The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy
Lead Sponsor:
Mendel AI
Collaborating Sponsors:
Cairo University
Conditions:
Oncology Pain
Chemotherapy-induced Peripheral Neuropathy
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This is a double blinded two-arm randomized case-only interventional trial. A total of 60 patients who are to receive Paclitaxel to be included and allocated in two groups. The protocol is to be revie...
Eligibility Criteria
Inclusion
- All patients, 18 years of age or older, with a cancer treated with Paclitaxel
- Patients must have a life expectancy of at least 24 weeks.
- Patients must sign an informed consent.
- Patients may have a grade 0 (chemotherapy naive) or 1 neuropathy (history of prior chemotherapy) prior to entry.
- Patient matching high risk on the CIPN risk stratification scoring system
Exclusion
- Patients with symptomatic brain metastases.
- Pregnant women or nursing mothers. Patients of child bearing potential must use adequate contraception.
- Patients may receive no other concurrent complementary medicines during this study.
- Patients with neuropathy induced diabetes.
- Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections.
Key Trial Info
Start Date :
February 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04737967
Start Date
February 15 2021
End Date
October 1 2021
Last Update
February 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine Cairo University - Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine
Cairo, Egypt, 11562